The global secondary progressive multiple sclerosis drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Secondary progressive MS (SPMS) is a form of MS that occurs after relapsing-remitting MS. The disease varies across individuals and does not occur in all the patients who priorly have RRMS. The major factor contributing to the growth of the market is the increasing prevalence of the disease across the globe.

According to the National Multiple Sclerosis Society (NMSS), an estimated 50% of patients who are diagnosed with relapsing-remitting MS (RRMS) would transition to secondary-progressive MS (SPMS) within 10 years. Additionally, within 25 years, 90% of patients who are diagnosed with relapsing-remitting MS (RRMS) would evolve to secondary-progressive MS (SPMS). Hence, the rising prevalence of the disease is driving the demand for secondary progressive multiple sclerosis drugs.

Some major players operating in the market include Actelion Ltd., Biogen Inc., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in March 2019, Novartis announced the approval of Mayzent (siponimod) from the FDA. It is an oral drug used for the treatment of relapsing forms of multiple sclerosis, including secondary progressive multiple sclerosis (SPMS) with active disease, relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) in adults.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Actelion Ltd., Biogen Inc., and Novartis International AG, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Secondary Progressive Multiple Sclerosis Drug Market Report by Segment

By Type 

• Inebilizumab
• GLX-1112
• DC-TAB
• Etomoxir
• IB-MS
• Others

By Application 

• Hospital
• Clinic
• Others

Global Secondary Progressive Multiple Sclerosis Drug Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa